Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Gains from Sales and Divestitures (2017 - 2024)

Historic Gains from Sales and Divestitures for Iradimed (IRMD) over the last 8 years, with Q4 2024 value amounting to $51069.0.

  • Iradimed's Gains from Sales and Divestitures fell 591.91% to $51069.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $51069.0, marking a year-over-year decrease of 591.91%. This contributed to the annual value of $51069.0 for FY2024, which is 591.91% down from last year.
  • As of Q4 2024, Iradimed's Gains from Sales and Divestitures stood at $51069.0, which was down 591.91% from $54282.0 recorded in Q4 2023.
  • Iradimed's 5-year Gains from Sales and Divestitures high stood at $139890.0 for Q3 2020, and its period low was $9345.0 during Q4 2020.
  • For the 5-year period, Iradimed's Gains from Sales and Divestitures averaged around $62839.5, with its median value being $52675.5 (2023).
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first tumbled by 9005.73% in 2020, then soared by 52760.83% in 2021.
  • Over the past 5 years, Iradimed's Gains from Sales and Divestitures (Quarter) stood at $9345.0 in 2020, then soared by 527.61% to $58650.0 in 2021, then tumbled by 30.51% to $40758.0 in 2022, then soared by 33.18% to $54282.0 in 2023, then decreased by 5.92% to $51069.0 in 2024.
  • Its Gains from Sales and Divestitures stands at $51069.0 for Q4 2024, versus $54282.0 for Q4 2023 and $40758.0 for Q4 2022.